Association between Three Therapeutic Strategies and Clinical Outcomes of 2009 FIGO Stage IB2/IIA2 Cervical Cancer
Table 3
Effect of prognostic factors on survival in univariate analyses.
Factors
n
3 y OS (%)
3 y PFS (%)
Age (years)
>45
114
88.6
0.311
86.0
0.431
≤45
92
83.7
81.5
Pretreatment hemoglobin
≥115
110
87.3
0731
86.4
0.362
＜115
96
84.9
81.34
Differentiation degree
G1-2
156
89.1
0.05
85.9
0.238
G3
50
78.0
78.0
Histology type
SCC
174
87.4
0.384
84.5
0.736
Non-SCC
32
81.3
81.3
Stage
IB2
126
86.5
0.982
84.1
0.914
IIA2
80
86.3
83.8
Tumor size
>4 cm
100
88.0
0.786
87.0
0.471
>5 cm
81
85.2
81.5
>6 cm
25
84.0
80.0
Therapeutic regimen
PST
104
87.5
0.856
85.6
0.424
NAC + RS
53
84.9
79.2
CCRT
49
85.7
85.7
Lymph node metastasis#
Yes
36
86.1
0.968
82.3
0.964
No
121
86.8
83.5
Vascular tumor thrombus#
Yes
20
80.0
0.428
80.0
0.738
No
137
87.6
83.9
Vaginal margin#
Yes
4
75.0
0.396
75.0
0.545
No
153
86.9
83.7
Deep stromal invasion#
Yes
105
81.8
0.157
81.0
0.280
No
52
92.3
88.5
#For lymph node metastasis, vascular tumor thrombus, vaginal margin, and deep stromal invasion, only 157 patients in the PST and NAC + RS groups were included in the statistical analysis.
